Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher I Li

Showing results (71-80 of 276) with videos related to

Pageof 28
Sort By:
Cancer Research|March 25, 2021
Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma <i>In Situ</i>Christopher I Li, Meghan R Flanagan, Mei-Tzu C Tang, et al.
Breast Cancer Research and Treatment|August 31, 2015
Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational studyMatthew F Buas, Jung-hyun Rho, Xiaoyu Chai, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 21, 2005
Differences in survival by histologic type of pancreatic cancerMegan Dann Fesinmeyer, Melissa A Austin, Christopher I Li, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 16, 2017
Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare PopulationLu Chen, Jessica Chubak, Denise M Boudreau, et al.
Cancer Research|August 27, 2009
Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancerChristopher I Li, Janet R Daling, Peggy L Porter, et al.
Cancer Research|September 23, 2017
Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare AnalysisLu Chen, Jessica Chubak, Denise M Boudreau, et al.
Journal of the National Cancer Institute|October 25, 2011
Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancerGenevieve M Monsees, Kathleen E Malone, Mei-Tzu C Tang, et al.
British Journal of Haematology|November 30, 2012
Evaluation of seasonality in the diagnosis of acute myeloid leukaemia among adults in the United States, 1992-2008Gregory S Calip, Jean A McDougall, Mark C Wheldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancerChristopher I Li, Janet R Daling, Peggy L Porter, et al.
Breast Cancer Research and Treatment|March 28, 2014
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapyGaia Pocobelli, Polly A Newcomb, Christopher I Li, et al.
Pageof 28

Showing results (71-80 of 276) with videos related to

Sort By:
Pageof 28
Cancer Research|March 25, 2021
Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma <i>In Situ</i>Christopher I Li, Meghan R Flanagan, Mei-Tzu C Tang, et al.
Breast Cancer Research and Treatment|August 31, 2015
Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational studyMatthew F Buas, Jung-hyun Rho, Xiaoyu Chai, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 21, 2005
Differences in survival by histologic type of pancreatic cancerMegan Dann Fesinmeyer, Melissa A Austin, Christopher I Li, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 16, 2017
Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare PopulationLu Chen, Jessica Chubak, Denise M Boudreau, et al.
Cancer Research|August 27, 2009
Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancerChristopher I Li, Janet R Daling, Peggy L Porter, et al.
Cancer Research|September 23, 2017
Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare AnalysisLu Chen, Jessica Chubak, Denise M Boudreau, et al.
Journal of the National Cancer Institute|October 25, 2011
Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancerGenevieve M Monsees, Kathleen E Malone, Mei-Tzu C Tang, et al.
British Journal of Haematology|November 30, 2012
Evaluation of seasonality in the diagnosis of acute myeloid leukaemia among adults in the United States, 1992-2008Gregory S Calip, Jean A McDougall, Mark C Wheldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancerChristopher I Li, Janet R Daling, Peggy L Porter, et al.
Breast Cancer Research and Treatment|March 28, 2014
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapyGaia Pocobelli, Polly A Newcomb, Christopher I Li, et al.
Pageof 28